Showing 2341-2350 of 3134 results for "".
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Expert Sets Record Straight on COVID-19 Vaccine/Fillers “Risk”https://modernaesthetics.com/news/expert-sets-record-straight-on-covid-19-vaccinefillers-risk/2473033/When FDA officials reviewed the data for Moderna’s COVID-19 vaccine, a data point garnered some attention. There seemed to be at least a temporal association between treatment with dermal fillers and non-serious adverse reactions to the vaccine in three study subjects. Modern Aesth
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- 2020 in Reviewhttps://modernaesthetics.com/news/2020-in-review-1/2473031/• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched. Even in the midst of the international COVI
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- ZO Skin Health Adds Colleen Goggins to Board of Directorshttps://modernaesthetics.com/news/zo-skin-health-adds-colleen-goggins-to-board-of-directors/2473024/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- Demandforce Launches Online Booking Functionalityhttps://modernaesthetics.com/news/demandforce-launches-online-booking-functionality/2473020/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche
- Crown Aesthetics’ SkinPen Precision Scores Class IIa CE Certification from the British Standards Institutionhttps://modernaesthetics.com/news/crown-aesthetics-skinpen-precision-scores-class-iia-ce-certification-from-the-british-standards-institution/2473019/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- Promising Results from Dysport Dose Escalation Studyhttps://modernaesthetics.com/news/promising-results-from-dysport-dose-escalation-study/2473018/Top-line results from a Phase 2 dose escalation study show that significantly more subjects treated with Dysport® at all four doses achieved a composite two grade improvement responder rate than those treated with placebo at one month. The study accessed the duration of ef